Development of novel benznidazole formulations: Physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease

被引:36
作者
Palmeiro-Roldan, Ricardo [1 ]
Fonseca-Berzal, Cristina [2 ,3 ,4 ]
Gomez-Barrio, Alicia [2 ,3 ,4 ]
Aran, Vicente J. [2 ,3 ,5 ]
Escario, Jose A. [2 ,3 ,4 ]
Torrado-Duran, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
机构
[1] Univ Complutense Madrid, Fac Pharm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] UCM UPM, Madrid, Spain
[3] CSIC, Madrid, Spain
[4] Univ Complutense Madrid, Fac Pharm, Dept Parasitol, E-28040 Madrid, Spain
[5] CSIC, Inst Quim Med, E-28006 Madrid, Spain
关键词
Benznidazole; Solid dispersions; Physicochemical characterization; Dissolution study; Trypanocidal activity; SOLID-STATE CHARACTERIZATION; CONTROLLED-RELEASE; BILE-SALTS; DISPERSION; DISSOLUTION; DRUG; ABSORPTION; BEHAVIOR; MIXTURE;
D O I
10.1016/j.ijpharm.2014.06.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This work aims to develop novel benznidazole (BZN) solid dispersions (SD) to improve its solubility and bioavailability properties. Low-substituted hydroxypropylcellulose (L-HPC) and sodium deoxycholate (NaDC) were evaluated as carriers. BZN solid dispersions containing different ratios of carrier were prepared by a freeze-drying process and characterized by SEM, powder X-ray diffraction (XRD), differential scanning calorimetry (DSC) and dissolution studies. The reduced BNZ crystallinity in the new formulations was confirmed by XRD, and supported by DSC. BNZ:L-HPC solid dispersion at a 1:3 ratio (w/w) (SD-1:3 L-HPC) improved the BNZ dissolution rate (85% at 5 min) in comparison with BNZ raw material (23% at 5 min). However, NaDC formulations showed a prolonged release (24% at 30 min for SD-1:3 NaDC), due to the formation of a sustained release matrix in acidic medium. In vivo studies performed in a murine model of Chagas disease showed that the formulation achieving the highest parasitemia suppression at a low dose of 25 mg/kg/day after five days of treatment was SD-1:3 L-HPC (60% of parasitemia suppression versus 33% of suppression exerted by BNZ), suggesting that BNZ:L-HPC systems enhance the bioavailability of the drug. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 30 条
[1]   Stability study of amorphous valdecoxib [J].
Ambike, AA ;
Mahadik, KR ;
Paradkar, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 282 (1-2) :151-162
[2]  
BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
[3]   Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt [J].
Chen, Yaping ;
Lu, Yi ;
Chen, Jianming ;
Lai, Jie ;
Sun, Jing ;
Hu, Fuqiang ;
Wu, Wei .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 376 (1-2) :153-160
[4]   Effects of Bile Salts on Gastrointestinal Absorption of Pravastatin [J].
Chun, In Koo ;
Lee, Kyung Min ;
Lee, Kyung Eun ;
Gwak, Hye Sun .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (07) :2281-2287
[5]   Changed crystallinity of mebendazole solid dispersion: Improved anthelmintic activity [J].
Garcia-Rodriguez, Juan J. ;
de la Torre-Iglesias, Paloma M. ;
Carmen Vegas-Sanchez, M. ;
Torrado-Duran, Susana ;
Bolas-Fernandez, Francisco ;
Torrado-Santiago, Santiago .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 403 (1-2) :23-28
[6]   Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt [J].
Guan, Peipei ;
Lu, Yi ;
Qi, Jianping ;
Niu, Mengmeng ;
Lian, Ruyue ;
Hu, Fuqiang ;
Wu, Wei .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2011, 6 :965-974
[7]   Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats [J].
Kim, Kyunghee ;
Yoon, Inkyung ;
Chun, Inkoo ;
Lee, Nayoung ;
Kim, Taekrho ;
Gwak, Hye Sun .
DRUG DELIVERY, 2011, 18 (01) :79-83
[8]   Formulation Development and Dissolution Rate Enhancement of Efavirenz by Solid Dispersion Systems [J].
Koh, P. T. ;
Chuah, J. N. ;
Talekar, Meghna ;
Gorajana, A. ;
Garg, S. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 75 (03) :291-301
[9]   Biological characterization of a β-galactosidase expressing clone of Trypanosoma cruzi CL strain [J].
Le-Senne, A ;
Muelas-Serrano, S ;
Fernández-Portillo, C ;
Escario, JA ;
Gómez-Barrio, A .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2002, 97 (08) :1101-1105
[10]   Development of novel formulations for Chagas' disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks [J].
Leonardi, Dario ;
Salomon, Claudiol. ;
Lamas, Maria C. ;
Olivieri, Alejandro C. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 367 (1-2) :140-147